ANIP
ANI Pharmaceuticals, Inc.
$72.29
+0.01
(+0.01%)
Mkt Cap
1.66B
Volume
333,921
52W Range
69.58-97
Sector
Healthcare
Beta
0.49
EPS (TTM)
4.83 USD
P/E Ratio
14.97
Revenue (TTM)
978.38M USD
Rev Growth (5Y)
+33.5%
EPS Growth (5Y)
+29.6%
AlphaVal · Fair Value
What we estimate one share is worth
$226.07
Undervalued
strong signal
68.0% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 883.37M | 614.38M | 486.82M | 316.38M | 216.14M | 208.47M | 206.55M | 201.58M | 176.84M | 128.62M | 76.32M | 55.97M |
| Net Income | 78.34M | (18.52M) | 18.78M | (47.90M) | (42.60M) | (22.55M) | 6.09M | 15.49M | (1.08M) | 3.93M | 15.38M | 28.75M |
| EPS | 3.50 | -1.04 | 0.95 | -3.05 | -3.40 | -1.88 | 0.51 | 1.33 | -0.09 | 0.34 | 1.34 | 2.61 |
| Free Cash Flow | 150.90M | 47.06M | 100.45M | (47.66M) | (20.32M) | (53.05M) | 18.08M | 56.16M | (68.57M) | (121.59M) | (15.42M) | (13.72M) |
| FCF / Share | 7.53 | 2.44 | 5.58 | -2.93 | -1.61 | -4.43 | 1.53 | 4.81 | -5.94 | -10.62 | -1.36 | -1.25 |
| Operating CF | 185.22M | 64.02M | 118.96M | (31.20M) | 3.32M | 15.27M | 45.63M | 67.07M | 39.42M | 27.47M | 17.26M | 22.03M |
| Total Assets | 1.44B | 1.28B | 904.42M | 760.09M | 771.60M | 461.19M | 456.79M | 430.60M | 412.14M | 322.86M | 285.26M | 263.71M |
| Total Debt | 325.19M | 624.09M | 285.67M | 286.52M | 287.37M | 185.69M | 185.75M | 183.01M | 201.51M | 120.64M | 113.43M | 110.69M |
| Cash & Equiv | 285.58M | 144.86M | 221.12M | 48.23M | 100.30M | 7.86M | 62.33M | 43.01M | 31.14M | 27.36M | 154.68M | 169.04M |
| Book Value | 540.72M | 428.53M | 457.60M | 338.54M | 358.74M | 195.70M | 212.79M | 197.26M | 174.76M | 169.65M | 160.08M | 139.78M |
| Return on Equity | 0.14 | -0.04 | 0.04 | -0.14 | -0.12 | -0.12 | 0.03 | 0.08 | -0.01 | 0.02 | 0.10 | 0.21 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 266.04M | 237.46M | 247.06M | 227.81M | 211.37M | 197.12M | 190.57M | 148.33M | 138.04M | 137.43M | 131.65M | 131.83M |
| Net Income | 24.71M | 29.49M | 27.49M | 24.13M | 8.55M | 15.68M | (10.28M) | (24.17M) | (2.29M) | 18.21M | 1.16M | 9.94M |
| EPS | 1.09 | 1.31 | 1.24 | 1.19 | 0.37 | 0.70 | -0.55 | -1.27 | -0.14 | 0.84 | 0.04 | 0.50 |
| Free Cash Flow | 67.99M | 47.05M | 6.51M | 37.89M | 68.90M | 15.14M | 13.38M | 7.66M | 12.96M | 13.69M | 39.96M | 27.62M |
| FCF / Share | 3.21 | 2.25 | 0.32 | 1.89 | 3.47 | 0.77 | 0.69 | 0.39 | 0.67 | 0.72 | 2.10 | 1.46 |
| Operating CF | 56.67M | 58.38M | 30.37M | 44.05M | 75.81M | 34.99M | 15.86M | 12.47M | 17.41M | 18.27M | 44.74M | 32.17M |
| Total Assets | 1.49B | 1.42B | 1.44B | 1.41B | 1.34B | 1.29B | 1.28B | 1.29B | 920.75M | 914.52M | 904.42M | 889.91M |
| Total Debt | 330.34M | 327.76M | 325.19M | 322.63M | 621.56M | 622.82M | 624.09M | 625.36M | 285.24M | 285.46M | 285.67M | 285.88M |
| Cash & Equiv | 360.21M | 311.18M | 285.58M | 262.61M | 217.80M | 149.80M | 144.86M | 144.98M | 240.11M | 228.60M | 221.12M | 193.08M |
| Book Value | 597.21M | 562.30M | 540.72M | 505.82M | 461.61M | 443.47M | 428.53M | 430.80M | 480.61M | 476.81M | 457.60M | 454.71M |
| Return on Equity | 0.04 | 0.05 | 0.05 | 0.05 | 0.02 | 0.04 | -0.02 | -0.06 | -0.00 | 0.04 | 0.00 | 0.02 |
ANIP News
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH)
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)
ANI Pharmaceuticals to Present at September Investor Conferences